Nelfinavir
Castleman Disease
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Castleman Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Siltuximab Centocor, Inc. | Phase 1 | CC |
Cetuximab M.D. Anderson Cancer Center | Phase 1 | CC |
Temsirolimus M.D. Anderson Cancer Center | Phase 1 | CC |
Valproic Acid M.D. Anderson Cancer Center | Phase 1 | CC |
Silmitasertib Cylene Pharmaceuticals | Phase 1 | CC |
Same molecule, other indications
Nelfinavir is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →